D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
AMLX holding history
Amylyx Pharmaceuticals, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AMLX overviewAll 13F holders of AMLXFull Q2 2026 holdings
- Shares (Q2 2026)
- 174,285
- Value
- $3.13M
- % of portfolio
- <0.1%
- Quarters held
- 16
- Since Q3 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 174,285 | $3.13M | <0.1% | +100,055+134.8% | Added | Holders |
| Q1 2026 | 74,230 | $1.03M | <0.1% | +1,006+1.4% | Added | Holders |
| Q4 2025 | 73,224 | $884.5K | <0.1% | +4,347+6.3% | Added | Holders |
| Q3 2025 | 68,877 | $936.0K | <0.1% | −82,625−54.5% | Reduced | Holders |
| Q2 2025 | 151,502 | $971.1K | <0.1% | −118,504−43.9% | Reduced | Holders |
| Q1 2025 | 270,006 | $955.8K | <0.1% | −36,738−12.0% | Reduced | Holders |
| Q4 2024 | 306,744 | $1.16M | <0.1% | −384,322−55.6% | Reduced | Holders |
| Q3 2024 | 691,066 | $2.24M | <0.1% | −617,115−47.2% | Reduced | Holders |
| Q2 2024 | 1,308,181 | $2.49M | <0.1% | +265,598+25.5% | Added | Holders |
| Q1 2024 | 1,042,583 | $2.96M | <0.1% | +495,618+90.6% | Added | Holders |
| Q4 2023 | 546,965 | $8.05M | <0.1% | −213,325−28.1% | Reduced | Holders |
| Q3 2023 | 760,290 | $13.9M | <0.1% | −829,754−52.2% | Reduced | Holders |
| Q2 2023 | 1,590,044 | $34.3M | 0.1% | −432,326−21.4% | Reduced | Holders |
| Q1 2023 | 2,022,370 | $59.3M | 0.1% | +638,638+46.2% | Added | Holders |
| Q4 2022 | 1,383,732 | $51.1M | 0.1% | +1,221,467+752.8% | Added | Holders |
| Q3 2022 | 162,265 | $4.57M | <0.1% | +162,265 | New | Holders |